Capital Management Associates (New York)’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Capital Management Associates (New York)’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-20,000	Closed	-$155K	–	127
2016 Q3	$155K	Hold	20,000	–	–	0.25%	114
2016 Q2	$112K	Hold	20,000	–	–	0.19%	112
2016 Q1	$108K	Hold	20,000	–	–	0.2%	106
2015 Q4	$174K	Hold	20,000	–	–	0.25%	130
2015 Q3	$168K	Buy	+20,000	New	+$319K	0.26%	131

Other funds holding SRNE

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Management Associates (New York)'s SRNE Position: Q4 2016 in Review

Capital Management Associates (New York) sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2016, closing a stake of 20,000 shares — an estimated $155K sold.

Capital Management Associates (New York) first reported a position in SRNE in Q3 2015 and held it in 5 quarters. The position peaked at $174K in Q4 2015. 68 funds tracked by Wall St. Rank hold SRNE as of Q4 2016.

Capital Management Associates (New York) reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Capital Management Associates (New York) sold 20,000 Sorrento Therapeutics, Inc. shares in Q4 2016, an estimated $155K.
Capital Management Associates (New York) first reported a position in Sorrento Therapeutics, Inc. in Q3 2015 and held it in 5 quarters.
Capital Management Associates (New York)'s Sorrento Therapeutics, Inc. position peaked at $174K in Q4 2015.
68 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2016.

Based on Capital Management Associates (New York)'s 13F filing for Q4 2016, filed 2 Feb 2017.